ICML 2019: Mogamulizumab in Cutaneous T-Cell Lymphoma
Posted: Friday, June 28, 2019
Based on a post hoc analysis of the phase III MAVORIC trial, Julia Scarisbrick, MD, of the University Hospital Birmingham, United Kingdom, and international colleagues reported “meaningful clinical benefit” with the CCR4-targeting monoclonal antibody mogamulizumab in patients previously treated with systemic therapies for stage IB/IIA mycosis fungoides. Although this trial was not being powered to determine therapeutic outcomes by disease stage, the investigators focused on the endpoints of time to next therapy, overall response, and compartmental response.
“Less advanced mycosis fungoides (stage IB/IIA) is a chronic skin malignancy that can involve blood and nodes and may require many lines of systemic therapy over the disease course with a reduced quality of life,” noted the investigators, who presented their findings at the 2019 International Conference on Malignant Lymphoma (ICML; Abstract 034).
A total of 372 patients with mycosis fungoides took part in this trial; 85 of them had stage IB/IIA disease and were the focus of the post hoc analysis. Of those with early-stage disease, more than three-quarters had received at least two systemic therapies. All study patients were randomly assigned to receive mogamulizumab or the histone deacetylase inhibitor vorinostat.
In patients with early-stage disease, the median time to next therapy was longer with mogamulizumab than vorinostat (stage IB: 11.5 vs. 3.0 months; stage IIA: 10.1 vs. 4.9 months). As for the overall response rate, it was 20% with mogamulizumab compared with 18.5% with vorinostat in patients with stage IB disease and 19% versus 0%, respectively, in those with stage IIA disease. Furthermore, mogamulizumab was associated with better compartmental response rates in those with stage IIA disease than in patients with stage IB disease (skin: 38% and 20%; blood: 75% and 0%; lymph node: 15% and 0%).
Disclosure: The study authors’ disclosure information can be found at lymphcon.ch.
